In Silico Theoretical Molecular Modeling for Alzheimer’s Disease: The Nicotine-Curcumin Paradigm in Neuroprotection and Neurotherapy

The aggregation of the amyloid-β-peptide (AβP) into well-ordered fibrils has been considered as the key pathological marker of Alzheimer‘s disease. Molecular attributes related to the specific binding interactions, covalently and non-covalently, of a library of compounds targeting of conformational scaffolds were computed employing static lattice atomistic simulations and array constructions. A combinatorial approach using isobolographic analysis was stochastically modeled employing Artificial Neural Networks and a Design of Experiments approach, namely an orthogonal Face-Centered Central Composite Design for small molecules, such as curcumin and glycosylated nornicotine exhibiting concentration-dependent behavior on modulating AβP aggregation and oligomerization. This work provides a mathematical and in silico approach that constitutes a new frontier in providing neuroscientists with a template for in vitro and in vivo experimentation. In future this could potentially allow neuroscientists to adopt this in silico approach for the development of novel therapeutic interventions in the neuroprotection and neurotherapy of Alzheimer‘s disease. In addition, the neuroprotective entities identified in this study may also be valuable in this regard.

[1]  J Carter,et al.  Molecular Pathology of Alzheimer's Disease , 2013 .

[2]  K. Ono,et al.  REVIEW: Curcumin and Alzheimer's Disease , 2010, CNS neuroscience & therapeutics.

[3]  G. Cole,et al.  Why Pleiotropic Interventions are Needed for Alzheimer's Disease , 2010, Molecular Neurobiology.

[4]  K. Dawson,et al.  Dual effect of amino modified polystyrene nanoparticles on amyloid β protein fibrillation. , 2010, ACS chemical neuroscience.

[5]  C. Chiamulera,et al.  Nicotine increases the expression of neurotrophin receptor tyrosine kinase receptor A in basal forebrain cholinergic neurons , 2010, Neuroscience.

[6]  L. Mucke Neuroscience: Alzheimer's disease , 2009, Nature.

[7]  H. Gendelman,et al.  Neurodegenerative disorders and nanoformulated drug development. , 2009, Nanomedicine.

[8]  V. Pillay,et al.  Trends in the Molecular Pathogenesis and Clinical Therapeutics of Common Neurodegenerative Disorders , 2009, International journal of molecular sciences.

[9]  G. Xie,et al.  Central composite design-based analysis of specific leaf area and related agronomic factors in cultivars of rapeseed (Brassica napus L.) , 2009 .

[10]  A. Abbott Neuroscience: The plaque plan , 2008, Nature.

[11]  W. Djoudi,et al.  Optimization of copper cementation process by iron using central composite design experiments , 2007 .

[12]  R. Kayed,et al.  Small Molecule Inhibitors of Aggregation Indicate That Amyloid β Oligomerization and Fibrillization Pathways Are Independent and Distinct* , 2007, Journal of Biological Chemistry.

[13]  D. Selkoe,et al.  Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.

[14]  K. Ono,et al.  Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer’s disease , 2006, Cellular and Molecular Life Sciences CMLS.

[15]  P. Brundin,et al.  Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases. , 2006, International journal of pharmaceutics.

[16]  G. He,et al.  Optimization of angiotensin I-converting enzyme (ACE) inhibition by rice dregs hydrolysates using response surface methodology. , 2005, Journal of Zhejiang University. Science. B.

[17]  C. Chirita,et al.  Triggers of full-length tau aggregation: a role for partially folded intermediates. , 2005, Biochemistry.

[18]  Takeshi Iwatsubo,et al.  Inhibition of Heparin-induced Tau Filament Formation by Phenothiazines, Polyphenols, and Porphyrins* , 2005, Journal of Biological Chemistry.

[19]  R. Sabaté,et al.  Temperature dependence of the nucleation constant rate in beta amyloid fibrillogenesis. , 2005, International journal of biological macromolecules.

[20]  Fusheng Yang,et al.  Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo* , 2005, Journal of Biological Chemistry.

[21]  J. Weiser,et al.  Accurate Calculations of Ligand Binding Free Energies: Chiral Separation with Enantioselective Receptors , 2004 .

[22]  Kenjiro Ono,et al.  Curcumin has potent anti‐amyloidogenic effects for Alzheimer's β‐amyloid fibrils in vitro , 2004, Journal of neuroscience research.

[23]  K. Janda,et al.  Glycation of the amyloid β-protein by a nicotine metabolite: A fortuitous chemical dynamic between smoking and Alzheimer's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Ş. Niculescu Artificial neural networks and genetic algorithms in QSAR , 2003 .

[25]  J. Kemp,et al.  Controlling Polymerization of β-Amyloid and Prion-derived Peptides with Synthetic Small Molecule Ligands* , 2000, The Journal of Biological Chemistry.

[26]  P. Schmidt,et al.  Optimization of an effervescent tablet formulation containing spray dried L-leucine and polyethylene glycol 6000 as lubricants using a central composite design. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[27]  R. Majocha,et al.  Indomethacin Reverses the Microglial Response to Amyloid β-Protein , 1998, Neurobiology of Aging.

[28]  J. Hardy,et al.  The presenilins and Alzheimer's disease. , 1997, Human molecular genetics.

[29]  John Hardy,et al.  Amyloid, the presenilins and Alzheimer's disease , 1997, Trends in Neurosciences.

[30]  W. L. Jorgensen,et al.  Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .

[31]  M. Hurle,et al.  Selective Inhibition of A Fibril Formation , 1996, The Journal of Biological Chemistry.

[32]  P. Fraser,et al.  Conformation and fibrillogenesis of Alzheimer A beta peptides with selected substitution of charged residues. , 1994, Journal of molecular biology.

[33]  J. Morley,et al.  Topography of a binding site for small amnestic peptides deduced from structure-activity studies: relation to amnestic effect of amyloid beta protein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Reed,et al.  Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer's disease beta A4 peptides. , 1992, Journal of molecular biology.

[35]  J. Reed,et al.  Aggregation and secondary structure of synthetic amyloid βA4 peptides of Alzheimer's disease , 1991 .

[36]  S. Loewe,et al.  Über Kombinationswirkungen , 1926, Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie.

[37]  D. Selkoe Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[38]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[39]  C. Glabe Amyloid accumulation and pathogensis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar Abeta. , 2005, Sub-cellular biochemistry.

[40]  Irene T. Weber,et al.  Molecular mechanics calculations on protein-ligand complexes , 2002 .

[41]  R. Majocha,et al.  Indomethacin reverses the microglial response to amyloid beta-protein. , 1998, Neurobiology of aging.